Answers to questions frequently asked about ECT.
D000367:Age Factors; D000771:Anesthesia, Intravenous; D001925:Brain Damage, Chronic / Q000209:etiology; D001932:Brain Neoplasms / Q000150:complications; D003863:Depression / Q000628:therapy*; D004565:Electroconvulsive Therapy / Q000009:adverse effects / Q000401:mortality; D005481:Flurothyl / Q000627:therapeutic use; D005555:Forensic Psychiatry; D007839:Functional Laterality; D006801:Humans; D007258:Informed Consent; D002532:Intracranial Aneurysm / Q000150:complications; D008094:Lithium / Q000494:pharmacology; D008723:Methohexital; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009203:Myocardial Infarction / Q000150:complications; D009518:New York; D010259:Paranoid Disorders / Q000628:therapy; D010433:Pentylenetetrazole / Q000627:therapeutic use; D011292:Premedication; D012110:Reserpine / Q000627:therapeutic use; D012559:Schizophrenia / Q000628:therapy*; D013390:Succinylcholine / Q000627:therapeutic use
D008996:Monoamine Oxidase Inhibitors; D012110:Reserpine; D008094:Lithium; D005481:Flurothyl; D008723:Methohexital; D013390:Succinylcholine; D010433:Pentylenetetrazole